首页> 外文OA文献 >In vitro and in vivo comparison of different grades of chitosan with common surgical hemostats
【2h】

In vitro and in vivo comparison of different grades of chitosan with common surgical hemostats

机译:不同级别壳聚糖与常用手术止血剂的体内外比较

摘要

The most common cause of significant intra-operative bleeding is inadequate surgical hemostasis. Nearly all reviews of intra-operative and early post-operative bleeding point that 75% to 90% of all bleeding is technical in nature. Whatever the cause, uncontrolled bleeding can lead to a combination of factors which may further exacerbate the problem of a vicious bloody circle. Dilutional thrombocytopenia, platelet dysfunction and consumption of clotting factors present a difficult problem to address as continual blood loss continue to compound the problem while blood component replacement therapy attempts to correct the deficiency. Our study aims to compare haemostatic efficacy of different grades of chitosan compared to the common haemostatic surgical hemostats. We hypothesize that chitosan based hemostats are superior to the common surgical hemostats in inducing platelet aggregation, affecting Prothrombin Time and Partial Thromboplastin Time and red cell aggregation. There were two parts to the study. In the in vitro study blood sample was obtained from the blood bank. Blood sample was collected utilizing the CP2D/AS-3 systems with additive solution (AS-3,Nutricel® ) to maintain red blood cell viability. Collected whole blood was separated into four separate components ( whole blood, heparinized whole blood, platelet rich and platelet poor plasma) . In the platelet aggregation test, stirred citrated PRP was contacted with 3.5 mg of each haemostatic agent premoistened with 100 micro liter of phosphate-buffered saline (PBS) in a test tube (as would be used in traditional platelet aggregometry). Aliquots of supernatant (100 micro liter) were removed every 5 minute for a total of 15 minutes and the platelet count was measured in triplicate utilizing an electronic cell counter (XT2000i Sysmax Analyzer, Sysmex America Inc., Mundelein, Illinois); platelet counts from each experimental aliquot were normalized using counts from unreacted PRP. For each haemostatic agent three independent sets of experiments were performed. A similar set of platelet aggregation experiments was performed using the haemostatic sponge agents ( 3 Different grades of Chitosan, Lyostypt® , and Surgicel®) premoistened with PBS. In the PT/PTT test, each haemostatic agent was reacted with platelet rich and platelet poor plasma. The serum was centrifuged to remove possible deposition. Six parallel experiments were conducted to measure PT and APTT of the serum using a hemostasis analyzer (Stago STA Compact Haemostatic Analyzer, Diamond Diagnostics, MA. USA) In the red cell aggregation test, each haemostatic agent was reacted with whole blood, heparinized blood and platelet poor blood. The blood with haemostatic agents were left to stand and the erythrocyte sedimentation rate was measured with the Sedy400 sedimentation analyzer. In the animal experiment, 36 Sprague-Dawley rats were utilized. Under general anesthesia, via a midline laparotomy the right and left kidneys were isolated. Heminephrectomies were carried out and hemostats were applied to the cut surface and time taken to hemostasis was tabulated. In the platelet aggregation test, no definite trend in platelet aggregation was observed. No CMC 36 3% showed the lowest platelet count of all haemostatic agents at 5 minutes. Lyostypt® and Surgicel® were superior compared to chitosan hemostats at 10 minutes of contact. In the coagulation test (PT/PTT ) mean prothrombin time for Chitosan (NoCMC 8%) was the shortest in platelet rich plasma. Mean partial thromboplastin time was the shortest for Chitosan (NoCMC 3%) in platelet rich plasma. In platelet poor plasma, the shortest prothrombin time was seen in both the Chitosan hemostats( NoCMC 3% and NoCMC8%). Partial thromboplastin time was shortest for Chitosan (NoCMC 3%) hemostat. In the red cell aggregation test, Chitosan hemostat(NoCMC 3%) demonstrated the highest erythrocyte sedimentation ratio in platelet poor blood as well as heparinized blood specimens. Chitosan hemostat (NoCMC 8%) demonstrated the highest erythrocyte sedimentation ratio in heparinized whole blood. In the animal experiment, there was no statistical difference between the hemostats in arresting bleeding from heminephrectomy specimens. The Chitosan hemostat(NoCMC 36 3%) however demonstrated the shortest time to hemostasis compared to the otherhemostats. From the study we concluded that Chitosan hemostats causes platelet to aggregate the earliest compared to other hemostats. They shorten prothrombin and partial thromboplastin time. They have been also found to aggregate red blood cells the most compared to other haemostatic agents.
机译:术中大量出血的最常见原因是手术止血不足。术中和术后早期出血的几乎所有评论都指出,所有出血的75%至90%本质上是技术性的。无论是什么原因,无法控制的出血都可能导致多种因素的组合,可能进一步加剧恶性血腥循环的问题。稀释性血小板减少症,血小板功能障碍和凝血因子的消耗是一个难以解决的问题,因为持续的失血继续使问题复杂化,而血液成分替代疗法则试图纠正这一缺陷。我们的研究旨在比较不同级别的壳聚糖与普通止血外科手术止血剂的止血效果。我们假设基于壳聚糖的止血剂在诱导血小板聚集,影响凝血酶原时间和部分凝血活酶时间以及红细胞聚集方面优于一般的手术止血剂。研究分为两个部分。在体外研究中,血液样本是从血库获得的。利用CP2D / AS-3系统和添加剂溶液(AS-3,Nutricel®)收集血液样本,以维持红细胞的生存能力。将收集的全血分为四个独立的成分(全血,肝素化全血,富含血小板的血浆和缺乏血小板的血浆)。在血小板凝集试验中,将搅拌的柠檬酸PRP与3.5 mg的每种止血剂接触,并在试管中预先用100微升磷酸盐缓冲盐水(PBS)润湿(与传统的血小板凝集法一样)。每5分钟取出等分试样的上清液(100微升),共15分钟,并使用电子细胞计数器(XT2000i Sysmax Analyzer,Sysmex America Inc.,Mundelein,Illinois)一式三份测量血小板计数。使用未反应的PRP计数将每个实验等分试样的血小板计数标准化。对于每种止血剂,进行了三组独立的实验。使用预浸有PBS的止血海绵剂(3种不同的壳聚糖,和)进行了类似的血小板凝集实验。在PT / PTT测试中,每种止血剂都与富含血小板和缺乏血小板的血浆反应。离心血清以去除可能的沉积。使用止血分析仪(Stago STA紧凑型止血分析仪,美国马萨诸塞州钻石诊断公司)进行了六个平行实验,以测量血清的PT和APTT。在红细胞聚集测试中,每种止血剂均与全血,肝素化血和血小板血液不良。使具有止血剂的血液静置,并用Sedy400沉降分析仪测量红细胞沉降速率。在动物实验中,使用了36只Sprague-Dawley大鼠。在全身麻醉下,通过中线剖腹术分离右肾和左肾。进行半切开术,将止血剂应用于切开的表面,并记录止血时间。在血小板凝集试验中,未观察到明确的血小板凝集趋势。在5分钟内,没有3%的CMC 36显示出所有止血剂中最低的血小板计数。与壳聚糖止血药接触10分钟后,Lyostypt®和Surgicel®优于。在凝血试验(PT / PTT)中,壳聚糖的平均凝血酶原时间(NoCMC 8%)在富含血小板的血浆中最短。富含血小板的血浆中壳聚糖的平均部分凝血活酶时间最短(NoCMC 3%)。在贫血小板的血浆中,两种壳聚糖止血剂的凝血酶原时间最短(NoCMC 3%和NoCMC8%)。壳聚糖止血剂(NoCMC 3%)的部分凝血活酶时间最短。在红细胞聚集试验中,壳聚糖止血剂(NoCMC 3%)在血小板贫血和肝素化血液样本中显示出最高的红细胞沉降率。壳聚糖止血剂(NoCMC 8%)在肝素化全血中显示出最高的红细胞沉降率。在动物实验中,止血剂在止血肾切除术标本中止血方面没有统计学差异。与其他止血药相比,壳聚糖止血药(NoCMC 36 3%)显示出最短的止血时间。从研究中我们得出结论,与其他止血药相比,壳聚糖止血药可导致血小板聚集最早。它们缩短了凝血酶原和部分凝血活酶的时间。与其他止血剂相比,它们还发现最多聚集红细胞。

著录项

  • 作者

    Sasidaran Ramesh;

  • 作者单位
  • 年度 2011
  • 总页数
  • 原文格式 PDF
  • 正文语种
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号